Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cymabay Therapeutics (NQ: CBAY )

14.71 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cymabay Therapeutics

< Previous 1 2 3 Next >
Why CymaBay Therapeutics Stock Is Sinking This Week
The stock has given up some of its gains but remains up more than 130% year to date. 
Via The Motley Fool
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
The company is about to reap more money than previously expected from a new capital-raising effort. 
Via The Motley Fool
Why CymaBay Therapeutics Stock Popped Again Today
Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising. 
Via The Motley Fool
Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics. 
Via Benzinga
Analyst Expectations for CymaBay Therapeutics's Future
Via Benzinga
Why CymaBay Therapeutics Stock Is Jumping Today
The momentum continues after CymaBay reported great clinical results on Thursday. 
Via The Motley Fool
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
The company is working on a treatment for a liver disease that can cause severe itching. 
Via Investor's Business Daily
Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. Lantronix, Inc. (NASDAQ: LTRX) shares jumped 26.3% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
CymaBay Therapeutics Inc (NASDAQ: CBAY) released topline results from its Phase 3 pivotal RESPONSE study of seladelpar for adult patients with  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Climbs to New 52-Week High
Via Investor Brand Network
Earnings Preview For CymaBay Therapeutics
Via Benzinga
7 Analysts Have This to Say About CymaBay Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
Via Benzinga
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
Why Shares of CymaBay Therapeutics Are Soaring Friday
A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy. 
Via The Motley Fool
Analyst Expectations for CymaBay Therapeutics's Future
Via Benzinga
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of  
Via Benzinga
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:  
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
Expert Ratings for CymaBay Therapeutics
Via Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Dow Surges 200 Points; Constellation Brands Posts Upbeat Results
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.63% to 34,338.23 while the NASDAQ rose 1.05%... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
Following the FDA rejection, Intercept will restructure to focus on rare liver diseases. 
Via Investor's Business Daily
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... 
Via Benzinga
Why CymaBay Therapeutics Stock Nose-Dived This Week
Investors did not warmly greet the latest news from the biotech. 
Via The Motley Fool
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.